316 related articles for article (PubMed ID: 32272815)
1. The Potential of Long-Acting, Tissue-Targeted Synthetic Nanotherapy for Delivery of Antiviral Therapy Against HIV Infection.
Halling Folkmar Andersen A; Tolstrup M
Viruses; 2020 Apr; 12(4):. PubMed ID: 32272815
[TBL] [Abstract][Full Text] [Related]
2. Recent developments of nanotherapeutics for targeted and long-acting, combination HIV chemotherapy.
Gao Y; Kraft JC; Yu D; Ho RJY
Eur J Pharm Biopharm; 2019 May; 138():75-91. PubMed ID: 29678735
[TBL] [Abstract][Full Text] [Related]
3. Lopinavir/ritonavir: a review of its use in the management of HIV infection.
Cvetkovic RS; Goa KL
Drugs; 2003; 63(8):769-802. PubMed ID: 12662125
[TBL] [Abstract][Full Text] [Related]
4. Novel antiretroviral combinations in treatment-experienced patients with HIV infection: rationale and results.
Taiwo B; Murphy RL; Katlama C
Drugs; 2010 Sep; 70(13):1629-42. PubMed ID: 20731472
[TBL] [Abstract][Full Text] [Related]
5. Emerging Trends in the Long-Acting Antiretroviral Therapy: Current Status and Therapeutic Challenges.
Labh R; Gupta R
Curr HIV Res; 2021; 19(1):4-13. PubMed ID: 32838720
[TBL] [Abstract][Full Text] [Related]
6. The Promise of Long-Acting Antiretroviral Therapies: From Need to Manufacture.
Gendelman HE; McMillan J; Bade AN; Edagwa B; Kevadiya BD
Trends Microbiol; 2019 Jul; 27(7):593-606. PubMed ID: 30981593
[TBL] [Abstract][Full Text] [Related]
7. Drug delivery strategies and systems for HIV/AIDS pre-exposure prophylaxis and treatment.
Nelson AG; Zhang X; Ganapathi U; Szekely Z; Flexner CW; Owen A; Sinko PJ
J Control Release; 2015 Dec; 219():669-680. PubMed ID: 26315816
[TBL] [Abstract][Full Text] [Related]
8. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
9. From in silico hit to long-acting late-stage preclinical candidate to combat HIV-1 infection.
Kudalkar SN; Beloor J; Quijano E; Spasov KA; Lee WG; Cisneros JA; Saltzman WM; Kumar P; Jorgensen WL; Anderson KS
Proc Natl Acad Sci U S A; 2018 Jan; 115(4):E802-E811. PubMed ID: 29279368
[TBL] [Abstract][Full Text] [Related]
10. Current status and prospects of HIV treatment.
Cihlar T; Fordyce M
Curr Opin Virol; 2016 Jun; 18():50-6. PubMed ID: 27023283
[TBL] [Abstract][Full Text] [Related]
11. Anti-HIV drug-combination nanoparticles enhance plasma drug exposure duration as well as triple-drug combination levels in cells within lymph nodes and blood in primates.
Freeling JP; Koehn J; Shu C; Sun J; Ho RJ
AIDS Res Hum Retroviruses; 2015 Jan; 31(1):107-14. PubMed ID: 25402233
[TBL] [Abstract][Full Text] [Related]
12. Interferon-associated therapies toward HIV control: The back and forth.
Noël N; Jacquelin B; Huot N; Goujard C; Lambotte O; Müller-Trutwin M
Cytokine Growth Factor Rev; 2018 Apr; 40():99-112. PubMed ID: 29555233
[TBL] [Abstract][Full Text] [Related]
13. Improving combination antiretroviral therapy by targeting HIV-1 gene transcription.
Le Douce V; Ait-Amar A; Forouzan Far F; Fahmi F; Quiel J; El Mekdad H; Daouad F; Marban C; Rohr O; Schwartz C
Expert Opin Ther Targets; 2016 Nov; 20(11):1311-1324. PubMed ID: 27266557
[TBL] [Abstract][Full Text] [Related]
14. Systems Approach to targeted and long-acting HIV/AIDS therapy.
Ho RJ; Yu J; Li B; Kraft JC; Freeling JP; Koehn J; Shao J
Drug Deliv Transl Res; 2015 Dec; 5(6):531-9. PubMed ID: 26315144
[TBL] [Abstract][Full Text] [Related]
15. Long-Acting Profile of 4 Drugs in 1 Anti-HIV Nanosuspension in Nonhuman Primates for 5 Weeks After a Single Subcutaneous Injection.
McConnachie LA; Kinman LM; Koehn J; Kraft JC; Lane S; Lee W; Collier AC; Ho RJY
J Pharm Sci; 2018 Jul; 107(7):1787-1790. PubMed ID: 29548975
[TBL] [Abstract][Full Text] [Related]
16. Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial.
Margolis DA; Gonzalez-Garcia J; Stellbrink HJ; Eron JJ; Yazdanpanah Y; Podzamczer D; Lutz T; Angel JB; Richmond GJ; Clotet B; Gutierrez F; Sloan L; Clair MS; Murray M; Ford SL; Mrus J; Patel P; Crauwels H; Griffith SK; Sutton KC; Dorey D; Smith KY; Williams PE; Spreen WR
Lancet; 2017 Sep; 390(10101):1499-1510. PubMed ID: 28750935
[TBL] [Abstract][Full Text] [Related]
17. Approaches for CNS delivery of drugs - nose to brain targeting of antiretroviral agents as a potential attempt for complete elimination of major reservoir site of HIV to aid AIDS treatment.
Gupta S; Kesarla R; Omri A
Expert Opin Drug Deliv; 2019 Mar; 16(3):287-300. PubMed ID: 30779602
[TBL] [Abstract][Full Text] [Related]
18. Preparation and characterization of anti-HIV nanodrug targeted to microfold cell of gut-associated lymphoid tissue.
Roy U; Ding H; Pilakka-Kanthikeel S; Raymond AD; Atluri V; Yndart A; Kaftanovskaya EM; Batrakova E; Agudelo M; Nair M
Int J Nanomedicine; 2015; 10():5819-35. PubMed ID: 26425084
[TBL] [Abstract][Full Text] [Related]
19. Three HIV Drugs, Atazanavir, Ritonavir, and Tenofovir, Coformulated in Drug-Combination Nanoparticles Exhibit Long-Acting and Lymphocyte-Targeting Properties in Nonhuman Primates.
Perazzolo S; Shireman LM; Koehn J; McConnachie LA; Kraft JC; Shen DD; Ho RJY
J Pharm Sci; 2018 Dec; 107(12):3153-3162. PubMed ID: 30121315
[TBL] [Abstract][Full Text] [Related]
20. Structural and pharmacological evaluation of a novel non-nucleoside reverse transcriptase inhibitor as a promising long acting nanoformulation for treating HIV.
Kudalkar SN; Ullah I; Bertoletti N; Mandl HK; Cisneros JA; Beloor J; Chan AH; Quijano E; Saltzman WM; Jorgensen WL; Kumar P; Anderson KS
Antiviral Res; 2019 Jul; 167():110-116. PubMed ID: 31034849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
